




Dear Reader,

A new year is always a great opportunity to start new initiatives and to implement new plans. Here are some exciting news from HEALTH: As of January 2023, our institute has a new name: HEALTH – Institute for Biomedical Research and Technologies.

In 2022 we launched a strategic development for the upcoming years with the motto "Turn something good into something even better". Following this new strategy we will focus on our strengths and align our competencies. This newsletter summarizes our strategic focus areas which we are starting to implement in January 2023: Pharmacological Research in the Skin, Pharmacological Research in the Brain, Metabolic Research and Digital Healthcare. To be able to focus on our new strategy we had to let go and we are thus no longer active in the field of medical sensors.

Kind regards,

Dr. Franz Feichtner and Dr. Thomas Pieber Directors JOANNEUM RESEARCH HEALTH



Pharmacological Research in the Skin

We are investigating pharmacological principles of the skin to enable the development of effective and affordable therapies with minimal side effects for people with skin diseases.

Our latest publication in this area:

Hummer, J., Birngruber, T., Sinner, F., Page, L., Toner, F., Roper, C. S., Moore, D. J., Baker, M. B., & Boncheva Bettex, M. (2022). Optimization of topical formulations using a combination of in vitro methods to quantify the transdermal passive diffusion of drugs. International Journal of Pharmaceutics, 620, 121737.(DOI)

Pharmacological Research in the Brain

We are doing pharmacological research in the healthy and the diseased brain to enable the development of effective therapies that can be tailored to each individual patient with a neurological disease.

Our latest publication in this area:

Altendorfer-Kroath T, Hummer J, Birngruber T. In vivo monitoring of brain pharmacokinetics and pharmacodynamics with cerebral Open Flow Microperfusion. Biopharm Drug Dispos [Internet]. 2023 Jan 17. (DOI)





Metabolic Research

We are applying our technologies to investigate the basic principles of metabolism and thus enable new treatments of widespread metabolic diseases such as diabetes and obesity, as well as an improvement in general aging processes.

Our latest publication in this area:

Zügner, E., Yang, H.-C., Kotzbeck, P., Boulgaropoulos, B., Sourij, H., Hagvall, S., Elmore, C. S., Esterline, R., Moosmang, S., Oscarsson, J., Pieber, T. R., Peng, X.-R., & Magnes, C. (2022). Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism. International Journal of Molecular Sciences, 23(14), 7966. (DOI)

Digital Healthcare

We contribute to a meaningful digitization of processes and decisions in healthcare to improve the quality of treatment while giving staff more time to work with people.

Our latest publication in this area:

Gutheil, J., & Donsa, K. (2022). SAINTENS: Self-Attention and Intersample Attention Transformer for Digital Biomarker Development Using Tabular Healthcare Real World Data. In Stud Health Technol Inform (pp. 212–220). (DOI)



Visit our website to stay up-to-date and learn more about our focus areas



JOANNEUM RESEARCH Forschungsgesellschaft mbH Leonhardstraße 59 8010 Graz, Austria

f y in O D





Visit us on



phone: +43 316 876-0 prm@joanneum.at

<u>Imprint</u>

You can edit your newsletter settings or unsubscribe completely.

Unsubscribe